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Summary 
The costimulatory molecule B7.1 provides a second signal  critical for T  cell activation. The 
distribution of this integral membrane protein is restricted to certain tissues where its level of 
expression is modulated by multiple  exogenous stimuli.  To identify the molecular basis  for 
specificity and inducibility, the chromatin configuration of the human B7.1  gene was exam- 
ined in intact nuclei from various cell types. The identification of a tissue-specific deoxyribo- 
nuclease I hypersensitive site ,',~3kb upstream of the transcription start site led to the character- 
ization of a cell type-specific enhancer region. This 183-bp region was both cell type specific 
and responsive to two distinct stimuli, lipopolysaccharide and dibutyryl cAMP, known to reg- 
ulate B7.1 expression. Deletional and site-directed mutagenesis revealed the presence of multi- 
ple functionally critical ds elements within this region, one of which was a nuclear factor (NF)- 
gB consensus sequence. In B7.1-positive B  cells,  this element bound several members of the 
NF-KB family, transcription factors already implicated in signal transduction pathways relevant 
to B7.1 expression. This is the first description, to our knowledge, of regulatory elements that 
control expression of a gene encoding a B7 costimulatory molecule. 
E 
ffective activation of T  lymphocytes requires two sig- 
nals from APCs (for a review see reference 1). The first 
signal is delivered upon the binding of the clonally distrib- 
uted TCR to MHC-foreign antigen complexes on APCs. 
This interaction results in the  phosphorylation of cellular 
tyrosine kinases  and the induction of gene expression (2, 
3). The second signal is provided by the interaction of co- 
stimulatory  molecules  on  T  cells  with  their  ligands  on 
APCs (4). The delivery of signal one in the absence of sig- 
nal two can lead to T  cell paralysis or anergy (5-7). 
Of the known costimulatory molecules, the B7 family of 
proteins is arguably the most potent. This family consists of 
at least two members, B7.1  (CDS0)  (8) and B7.2  (CD86) 
(9-11), which interact with similar affinity with their coun- 
terreceptors, CD28 and CTLA4, on T  cells, although their 
affinity for CTLA4 is substantially greater than for CD28 
(12,  13).  Blocking the interaction of the B7 molecules by 
excess soluble CTLA4 during T  cell activation leads to hy- 
poresponsiveness  (14).  Not  surprisingly,  B7.1-deficient 
mice  have  substantially  reduced  immune  responses  (15). 
Blockade of B7.1  by mAb injection leads  to amelioration 
ofautoimmune experimental allergic encephalitis, a murine 
model of multiple sclerosis  (16), and prevents xenograft re- 
jection (17). 
The B7.1 and B7.2 molecules have similar but not iden- 
tical tissue distribution patterns. Both proteins are expressed 
on dendritic cells,  and B7.1  is expressed on activated but 
not resting T cells (18, 19). Resting B cells express low levels 
of B7.2 but not B7.1 whereas upon activation, B  cells ex- 
press substantial levels of both proteins (10,  20).  Similarly, 
macrophages  constitutively express  B7.2  and  can  be  in- 
duced to express higher levels of B7 proteins upon IFN-~/ 
treatment (21).  In general, in mice, cell surface B7.2 levels 
are higher than B7.1 levels, and the kinetics of induction of 
B7.2 are faster than those of B7.1 (22, 23). 
A large number of stimuli can induce B7.1 expression on 
resting,  surface-negative B  cells.  These include the  cyto- 
kine IL-4 (24),  Abs to the B  cell Ig receptor (23),  hgation 
of the B cell activation molecule CD40 (25),  the mitogens 
LPS and dextran sulfate (23),  transformation by EBV (26), 
and agents that activate protein kinase A, such as dibutyryl 
cyclic AMP (db-cAMP) 1 (27, 28). Since resting B  cells do 
not contain detectable transcripts for B7.1, it is likely that 
such induction occurs primarily at the transcriptional level. 
Similarly, B7.1-negative monocytes become B7.1 positive 
1Abbreviations used in this paper: db-cAMP, dibutyl cyclic  AMP; EMSA, 
electrophoretic  mobility  shift assay; HTLV-1,  human T cell leukemia vi- 
res type-l; NF-KB, nuclear factor r,B; NIB, nuclear isolation buffer; tk, 
thymidine kinase. 
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activation by antigen or transformation by human T  cell leu- 
kemia virus type-1  (HTLV-1)  (26).  Many of these stimuli 
have  been  shown  to  activate  the  nuclear  factor  (NF)  KB 
transcription factor in other systems. 
The  cDNAs  encoding  both  human  and  mouse  B7.1 
genes have been isolated (8, 30). Using the human cDNA as 
probe, four transcripts sized 1.7, 2.9, 4.2, and 10 kb were de- 
tected in normal and neoplastic B  cells. The 2.9 kb transcript 
was the major species in anti-Ig-activated B  cells whereas the 
1.7-kb  transcript predominated in B  tumor cell lines, such 
as  the  Raji  cell line  (30).  In  the  mouse,  three  transcripts, 
2.2, 3.9, and 10 kb were detected in spleen and transformed 
B  cells (8).  The  molecular basis for the  variation in  tran- 
script lengths has not been determined. The genomic orga- 
nization of both the human and mouse genes has also been 
reported (31, 32). In humans, the B7.1 locus spans ~32 kb. 
A  primer  extension  analysis  of mRNAs  from  Raft  and 
CHI  B  cells has  shown  that  transcription  of both  human 
and  mouse B7.1  initiates within about 60  nucleotides up- 
stream of the 5'  end of the existing cDNA clones (31, 32). 
However, no obvious promoter elements were observed in 
the  5'  flanking region  abutting  the  putative  transcription 
start sites. Recently,  Borrielio et  al.  (33)  used RACE  (5' 
reverse amplification cDNA  ends)  on RNA  isolated from 
CH1  B  cells to  extend  the  5'  end  of the previously pub- 
lished roB7.1 cDNA by 1.5 kb, suggesting that an additional 
5'  untranslated sequence  may account for the variation in 
transcript length. 
In  this  report,  we  describe  the  analysis  of the  human 
B7.1  promoter. We provide evidence for an enhancer re- 
gion located ~3  kb upstream of the first exon which deter- 
mines both cell type specificity and inducibility by certain 
stimuli.  Linker-scanning  mutagenesis  of  this  region  re- 
vealed the presence ofa NF-KB consensus binding site and 
several additional sites whose  integrity was  critical for en- 
hancer function. 
Materials and Methods 
Isolation, Cloning, and Sequencing of the 5' Flanking Region of the 
B7. I Gene.  A full-length human B7.1  cDNA was used to screen 
a leukocyte genomic DNA library in k EMBL-3 (a gift of Dr. S. 
Orkin,  Children's Hospital, Boston,  MA)  (34).  The  screening 
procedure  was  as  described  (35).  The  DNA  from  10  positive 
clones was prepared, digested with restriction endonucleases, and 
subjected to agarose gel electrophoresis. The separated DNA frag- 
ments were transferred to nitrocellulose filters and probed with 
32p-labeled oligonucleotides representing sequences derived from 
different domains of the B7.1 gene. The procedures ofprehybrid- 
ization, hybridization, and washing of  filters were as described (30). 
One  clone, kUT-1,  hybridized to probes from the  first  and 
second exons of the B7. 1 gene. The DNA of this clone was fur- 
ther mapped by digestion with restriction endonucleases, and var- 
ious  subfragments recovered from agarose gels  were  subcloned 
into pBluescript KS (Stratagene Inc., LaJolla, CA). A 3.3-kb SacI 
subclone containing the first exon was used to generate a series of 
nested deletions using the Erase-a-Base kit (Promega, Madison, 
WI). The  overlapping deletion clones were sequenced on both 
strands using dye-labeled terminator/Taq polymerase chemistry 
and analyzed on an automated fluorescence DNA sequencer (Ap- 
plied Biosystems, Inc., Foster City, CA). 
In addition, a 2.4-kb BamHI-SacI fragment was sequenced by 
the dideoxynucleotide chain-termination/extension method (36) 
and  Sequenase  (United  States  Biochemical  Corp.,  Cleveland, 
OH)  using B7.1-specific oligonucleotide primers. The sequence 
was analyzed with the Genetic Computer Group (GCG) package 
(37) and compared with those in the GenBank database. 
Cell Lines.  Human EBV-transformed B cell lines BL30, EBV5, 
and SKW were obtained from Dr. J. Fingeroth (Dana-Farber Can- 
cer Institute),  the  Nalm6-transformed pre-B  cell line was  pro- 
vided by Dr. J. Ritz (Dana-Farber Cancer Institute), and the BA 
cell line came from Dr. S. Lederman (Columbia University, New 
York).  Other  human  cell lines, including the  epitheloid carci- 
noma HeLa, the hepatocellular carcinoma HepG2, the leukemic 
T  cell line Jurkat, the small cell lung carcinoma NCI-H146,  the 
Burkitt  lymphoma  Raft  and  EBV-negative Burkitt  lymphoma 
Ramos,  and  the  mouse  myeloid cell line  M1  were  purchased 
from the American Type Culture  Collection (Rockville, MD). 
The human fibroblast GM00637  was obtained from the Coriell 
Institute  for  Medical  Research  (Camden,  NJ).  M12.4.1  is  a 
BALB/c B  lymphoma cell (38).  HeLa,  HepG2,  and GM00637 
were  grown  in  DME,  and  all  other  cells  were  cultured  in 
RPMI 1640 containing 10 mM Hepes, pH 7.3. All culture media 
were  supplemented  with  8%  heat-inactivated  FCS  (HyClone 
Laboratories, Inc.,  Logan,  UT),  2  mM L-glutamine,  100  U/ml 
penicillin, 100 b~g/ml streptomycin, and 50 btM 2-ME. The cul- 
ture medium for M1  also contained 100 b~M nonessential amino 
acids. 
Abs and Flow Cytometry.  Anti-hB7.1  mAb 133  (mouse IgM) 
(39) and anti-mB7.1  mAb 1G10 (rat IgG2a) (27) have been de- 
scribed previously. The mAbs MIgM,K and RIgG2a,K were pur- 
chased from PharMingen  (San Diego, CA) and used as isotype- 
matched  control  Abs  for  human  or  mouse  cells,  respectively. 
Flow cytometry analysis was carried out as described. Briefly, 5 ￿ 
10  s cells were incubated with either control Ab or anti-B7.1 mAb 
at 4~  in HBSS containing 3% BSA and 0.1% NAN3. After wash- 
ing, the human and mouse cells were stained with FITC-conju- 
gated  goat  anti-mouse  IgM  (Tago,  Inc.,  Burlingame,  CA)  or 
FITC goat anti-rat IgG (Kirkegaard &  Perry Laboratories Inc., 
Gaithersburg,  MD),  respectively. The  analysis  of the  cells  was 
performed  on  a  FACS  |  analyzer  (Becton  Dickinson  &  Co., 
Mountain View, CA). 
DNase I Hypersensitive Site Mapping.  Isolation and DNase I di- 
gestion of nuclei were performed as described (40).  Briefly, 108 
cells in log phase were harvested, washed with PBS,  and resus- 
pended in 20  ml of ice-cold nuclear isolation buffer (NIB)  (15 
mM Tris, pH 7.6, 60 mM KC1, 15 mM NaC1,  300 mM sucrose, 
5  mM  MgC12, and  0.5  mM  dithiothreitol [DTT])  containing 
0.4% NP-40. Cells were permeablized for 5 rain on ice and cen- 
trifuged at 3,000 g for 5 min. Nuclei collected were resuspended 
in 0.5 ml of NIB and aliquoted into five tubes containing 100 ~1 
of NIB plus 0-5 btg of DNase I. After 4 rain at room tempera- 
ture, the reactions were stopped by addition of 250 ~1 of stop so- 
lution (63 mM Tris, pH 8, 2.5 mM EDTA and 1.25% SDS) and 
50  ~1  of proteinase K  (5  mg/ml).  The  lysates  were  incubated 
overnight at 37~  and proteins were removed by phenol/chloro- 
form extraction. The  genomic DNAs isolated were digested by 
BamHI, SacI, or XhoI and separated by electrophoresis on agarose 
gels. The gels were blotted and hybridized to a 32p-labeled 295-bp 
ScaI-BamHl probe, spanning exon 1 of the hB7.1 gene (see Fig. 3). 
Expression Plasmid Construction.  The  3.3-kb  Sacl  and  5-kb 
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released from pBluescript  clones  and purified from agarose gels. 
These fragments were inserted into pSyncatI, an expression vector 
containing a promoterless  CAT reporter gene  (SynapSys, Bur- 
lington, MA). Similarly, the 5-kb BamHl fragment and a 2.8-kb 
EcoRl fragment containing the DH site B (see Fig. 1) were iso- 
lated and inserted into pSyncatlI, a vector that contains the mini- 
real herpes virus thymidine kinase (tk) promoter upstream of the 
CAT reporter gene. Subsequently, these clones were digested with 
a variety of restriction enzymes to systematically remove different 
parts of the larger fragments.  Subclones of the shorter B7.1 DNA 
fragments were regenerated by hgation of blunted ends. 
Transient Transfections, Induction, and CA T Assays.  Raft B cells 
were transfected by electroporation using an electroporator (Bio- 
Rad Laboratories, Hercules, CA) as described (41). HeLa cells were 
transfected  using the standard  calcium phosphate technique (42). 
Transfections ofBA B cells andJurkat T cells were performed us- 
ing  DEAE-dextran  as  described  (43). Briefly,  107  cells  were 
washed in STBS  (25 mM Tris,  pH 7.4,  137 mM NaC1, 5 mM 
KC1, 0.6  mM Na2HPO4,  0.7  mM CaCI2, and 0.5  mM MgC12) 
and resuspended in 1 ml of DEAE-dextran (200 I,  tg/rrd)  plus 6 Ixg 
of plasmid DNA.  Cells were treated  with DEAE-dextran/DNA 
mixture at room temperature for 30 man, washed once with com- 
plete medium, and plated.  Cells were harvested  48 h after trans- 
fection. 
M12.4.1  (abbreviated as M12 hereafter) B cells and M1 myeloid 
cells were transfected using an alternative DEAE-dextran method 
as previously described  (38). Transfected cells were split equally 
into two sets of plates and incubated for 24 h. db-cAMP and LPS 
(both from Sigma Chemical Co., St. Louis, MO) were added to 
appropriate  plates of M12 cells at 30 and 5 b~g/ml, respectively. 
M1 cells were treated with LPS at 10 ng/ml. Cells were harvested 
at 18 h after db-cAMP treatment or at 24 h after LPS stimulation. 
Protein concentration of cell extracts was measured by a protein 
assay kit (Bio-Rad Laboratories).  Equal amounts of protein were 
used in CAT assays and CAT activity was measured using thin- 
layer chromatography and liquid scintillation counting. CAT ac- 
tivities of hB7.1  DNA transfections  are expressed as fold increase 
over those  of the vector DNA transfections,  which were  arbi- 
trarily  assigned  a  value of 1.0. All transfections  were  repeated 
three times unless otherwise specified. The NF-KB p50 and p65 
expression constructs  were the gift of Dr. R. Sen (Brandeis Uni- 
versity, Waltham, MA). 
Mutagenesis of the B7.1 Enhancer.  Deletion and linker-scanning 
mutants of the 183-bp B7.1 enhancer were made by PCR using a 
panel of synthesized  oligonucleotides (oligos).  A  665-bp PvulI 
fragment was isolated from the 183-bp StuI-Apal enhancer pSyn- 
catlI clone and used as  the  PCP,. template.  The template con- 
tained pSyncatlI sequences and restrection sites SaclI and BamHI 
flanking the 5' and 3' end of the enhancer, respectively.  Oligos 
used to  construct the  5' and 3' deletions of the  enhancer also 
contained SaclI or BamHI sites, respectively.  The 3' portions of 
the enhancer were obtained by PCR with SaclI-containing  oli- 
gos  and an oligo downstream of the  enhancer, whereas  the  5' 
portions were obtained by PCR with BamHI-containing oligos 
and an oligo upstream of the enhancer. The central portion of the 
enhancer was obtained by PCR with a pair of the B7.1  oligos 
flanking the region. PCR. products were digested with Sacll and 
BamHI and different  portions of the  enhancer were  recovered 
from agarose gels and recloned into pSyncatII. 
Linker-scanning  mutagenesis was performed by a modified over- 
lap-extension method as described  (44). In total,  18 unique oligos 
were  designed to  contain a  10-bp mutant sequence flanked by 
15-bp template sequences  on either side. Each oligo was used in 
PCR. to introduce mutations into a specific 10-bp region of the 
enhancer without changing the enhancer length. PCR products 
were digested with SaclI and BamHI, purified from agarose gels, 
and cloned back into pSyncatlI. DNA sequencing was  used  to 
veil@ all mutant and flanking sequences. 
Electrophoretic Mobility Shift Assay and Ab Inhibition.  Small  scale 
nuclear extracts were prepared from 107 P,.aji B cells as described 
(45).  An electrophoretic mobility shift  assay (EMSA) was  per- 
formed as previously described  (46) in a 10-1xl final volume con- 
taining 8 mM Hepes, pH 7.4, 0.3 mM MgC12, 100 mM NaC1, 
10 mM KC1, 0.8 mM EDTA, 0.5  mM DTT, and 9% glycerol. 
Each binding reaction also included 2.5  p~g poly(dI-dC), 2  I~g 
nuclear extract,  and ~2 ￿  104 cpm of 32p-labeled probe. For Ab 
inhibition, antisera  against  p50,  p52,  p65,  c-R.el  and  R.el-B 
(Santa Cruz Biotechnology, Santa Cruz, CA) were added at 1 Ixg 
per reaction.  Oligo probes and specific or nonspecific competitors 
used in EMSA included -2983 to -2959 of the hB7.1  enhancer 
(5'-GGGAAAGGGGTTTTCCCAGCAGTCA-3'),  the  NF-KB 
sequence  of  the  lgK  enhancer  (5'-CAGAGGGGACTTTC- 
CGAGA-3') (47), and mutant 3 of the raiL-4 promoter -79 to 
-60 region (5'-ATAAAATTTGAACATGTAAA-3')  (45). The 
reaction mixtures were separated  on a 5% nondenaturing poly- 
acrylamide mini-gel at 80 V for 75 min. 
Results and Discussion 
Isolation  and  Characterization  of a  Human  B7.1  Genomic 
Clone.  To isolate a  genomic clone encoding the human 
B7. I  gene,  a  full-length cDNA  was  used  as  a  probe  to 
screen a  leukocyte genomic DNA library in h  EMBL-3. 
From ~6  ￿  105 plaques screened, 10 clones were isolated 
that remained positive on tertiary screening. These clones 
were then analyzed by Southern blot analysis after restric- 
tion enzyme digestion and hybridization with 32p-labeled 
oligonucleotide probes corresponding to sequences derived 
from different regions of the  cDNA.  One done, hUT-l, 
hybridized with probes from the first two  exons.  Further 
analysis of this  genomic  clone revealed that  it  contained 
"~14 kb of DNA upstream of the first exon with the  re- 
striction map shown in Fig. 1. 
3.9-kb of DNA flanking the first exon was sequenced on 
both  strands  (Fig.  2).  A  search  of  this  sequence  using 
FASTA of the GCG program in the GenBank database re- 
ve;Lled the presence of two alu repetitive sequences (Fig.  1, I 
and I/) frequently found in flanking regions and introns (48, 
49). No other significant similarities betweeen the hB7.1 5' 
2kb  I  I  B  E  SX  EB 
I  I  II  II 
DH Site B  DH Site A  +  + 
PSE  EBS  X 
I  II  I  III  I￿9 
I  ￿9 
1  2 
￿9  rT'r  ZI  "r 
Figure  1.  Restriction map of the hB7.1 5' genomic clone, hUT-1. 
(Arrows) Locations of two DNase I hypersensitive  sites, A and B.  (Solid 
boxes) Exons 1 and 2. Sequences  similar  to two alu repeats and one trans- 
poson element, Line 1, are marked by horizontal  lines and are designated 
as I,  II, and III, respectively. The abbreviations  of restriction enzymes 
used are as follow: BamHI (B), EcoRE (E), PacI (P), SacI (S), and XhoI (X). 
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TTAATTAAAAAAAAAAGAGTCACAGGCAGG AAGAGTAAGATGCCAAGTATAGGAGGAAGA GTGTGGTGGGTTAGTAAGAAGACGGCCCTC ACTCTGAACGAGGGCTAGCTCTGAAAGTCA CTTGTTTTCATTTTAAGCATTTTGGTGATT 
TCCATCTCAAAGAACCAGAAAGAATGTGAC AGCATTTTAAGAGGAAGAGGTGAACTCTCC  CACTTTGATGAGTTTGCTGCCAACTTTAGC AGGCTGTGGCACTCCTGGGAGCACCATAGC CTTAAACCCTAGATCAGCTGCCCTATGATG 
StuI  B7.1 Enhancer 
CGTGCAGGCCTTATAGACATGCCCAGATGA AGTCATATCTAAAAATGAACTTCTAAACCT  CACGGGAGGGTCATCTTAGAACATGAAAAA CTCCCCTGAAAATTTTTGTCAGTGCAACAG GTTTTGTTTACTTGGCAACAGTGA~CCCAC 
NF-~B  ApaI  Sacl 
TGTGGGAAAGGGGTTTTCCCAGCAGTCAGG CTAGCACCGTGGGCCCTGAGTAGGCAACCT GCAAATGACAGCACTGAGGCCACTGCCAGG ACCCAGCCCAGCCCTCCCTGTGGATGCTGA ACGGAAGGGTAGGAAGGTTGAGCTCAGGCC 
AGCTTTATCAGCATGAGGAGGTGAAGTGGC  TCCAAGGTCAAGAGCAGAAAGATGGAACCT TCATTTCCACAGAGATCATCCTGTTCAGGG GTAAACCAAAGGGCCAGGCTTCCCCTACGG TGTCGCAACAGCCTCTGCACCAACCTCTGA 
EcoRI 
GTGACAAAGCTGCATCTCCCTCTCGTCATC  TCTTCCTGCTGGGTCCTCTACAGTCTGTGA TTGTGTTTTCATTTCATTTATAATGTCTTT CATTGTACAA TATTTTTAATTTTTATGAA TTCAAATCTGTGTATCTTTTCTTTTTTCGT 
GGCTTCCAAGTTTTGTGT~CACCCT  AGAATTATAAAAATATACTTCATAAATTTA TCCTTTCAATTTTTCACATAAAAATTTTTA AAAGAATTTTTATGTGAATTATTTTTAAAA GAATTTCTTTTACTTTTATTACAGTAAAGC 
AIU II 
CAAGGATGGATTTACAAAAAAATAAGTGGC ACTAAAGAATTTACACTGAGGACCAGTAAT TCCTCCTTTATTCTTCTCCAACCCTGGGTC TGCTCCTCAGAACAAACTCATTTAAAGTTT TTTTGTTTTGTTTTGTTTTGTTTTTGAAAC 
AGAATCTTGCTCTGTCACCCAGGCTGGAGT GCAATGGCACAATCTTAGCTCACTGCAACC TCCC~CTCTGAAGTTCAAGCAAGTCTCATG TCTCACCCTTCCCAGTACCTGGGATTACAG GTATGCACCACTATGCCCAGTTTT~ 
TTTTTTTTTTTTTGGAGAGCTGGGGT~TCA TCACGTTGC42CAGCTGGCCTCGAACTCCTG GCCTCAAGTGATCCGCCCACCTCAGCCTCT CAAAGTGCTGGGATTACAGGCATGAGCCAC TGTGCCCAGCCTCCTTTTAAATCTTTTACT 
TGGTTTTGTTTTGTTTTGTTTTGTTTTCCA GTAATATACGTATTCGGGTTCGGCTTCCTT TGCCCGTCTTCATCCATCTCACCTCCAGTG TCCAGAAATTTACCTTAGAAATCTGTGGTC  CACACGTCATGCTCCTAGACACATTGTAGG 
AGGAAGAGGAATTAAACACATCCCATTAGT ACATAATCTTGGAAGAGAAGCCTTCTGAAT TTTACAATCAGGATTGGGGAAACTCTGTAA AGTACCTTCCTGGTGTTCCTTTCTTCCAGC  CTCTTTGATTAAGTCACATCAAAGCGCTAA 
Alu I 
TGGCAAAGTTGTTTAATGTGTGTTTCTCCA AGGCAGGTTAGGATTTCACTGGGATTCTTA AAATTTGAGGGTGTCTGTGATCGTCAAAAT TTGTATTCATGTAGTCCCTCATGAAATTTC TAAAACTCGGCTGC~TGCGGTGGCTCATGC 
CTGTAATCCCAGCACTTTGGGAC~zCCGAGG AGGG~TCAC31AGGTCAGGAGTTTGAGA  CCAGCCTGC42CAATATGGTGAAACCCCATC TCTACTAAAAATTTAAAAATTAGCCTGGCA TGGTGGCACACGCCTGTAGTCCCAGCTACT 
CAGGAGGCTGAGGCAGAAGAATTGCT~  CCCAGGAC43CGGAGGTTGCAGTGAGCCAAG ATTGCACCACTGCACTCCAGCC~  AGAGAAAGACTTCATCTAAAAAAAAAAAAA GAAAATAAATTTCTAAAACTCTGTATTTCT 
TTGAAAAATCACTTCCAGTGCATTGTAATA ATGTATC3%AGTAGAAGTGC4ZTAAAATCAGT  GAAAACATTTCTTTGATCTGAATAAATGTT CAAGAAAATAGAAAACATGAACTTACCTCC AATCTATGTTCCCTTTAC~TGTAA 
TGTTGATCTACTAGAGGTAAGGCAGGAATT GTCACATCCATATTCCTTGCAACTATTCAA AATATGCATCVfGAGACCAGAACAAGACACA GGTGAAGAAGGGTGCTCACTAGGCCCCTTC TGCCAATACAGAAGGAGACAGTGCAGTGGA 
GTCCTTTCATAGCAAGTTCTGCCTTCATGA TTTCCAAAGCTTCAGTATTCCAAATCTCAG GTGAATAGGGTGGTATCCACTAAGCTCTGC  CACTTGCTCTCTTTCTGGCTGGTGTGGGAA GGATGGCGTCTTTTTTTTTTTTTTTTTTTT 
GAGATGGAGTCTTGCTCTGTTACCCAAGCT GGATTGTAGTGTTGTGATCTCGGCTCACTG CAACCCATGCAAGGTGCTGTCAGGTTCCAC  CTGTGCAAACAAGTACACTGGTCCAGCATG GGTCAGCTGCTCACTCACAGGGGCTCCAGA 
EcoRI 
ATCCTACAAAGGGACACACAC-GGGTC-GGTG  GCAACCTAGTTGGAAATGGGAGTGATGGGC ATGACTAAAGTCTTCCTCATCCCACCAGAG GCGCACTCAACTGTGGCTAGGGTGACCAGA ATTCACTGTCCAGCGTGGCTC-CAGGAGCCC 
ACTCTCTGAAGATGGTGGGATTCAGAGGTG GGAGTAGAGTTGGGTGGTCTTGTGAGCTGA GCACTCTCCCAAAAGTGTCCCCTACATATG AGGTTGACAGCTTATTCCTGCAGGGACTCA C-GAGTAACTC~TGCTAAAACAAAACTT 
EcoNI 
GAGACCAGCACAGAAACAGCCAGCCCATGA ACCTGGCCTCCCATCACACAGCAAGGCTAG CCAGATGCCCCTCACTCTTCTCGGGCACCA TTCTTCTCCTCCCCTAGGCCCCCTGGTGCT 
CGGTGGTGAGGGAGGCTGCTGTGTGATTTG CCCCAGCCACAGCCTCTACAAAAGCAAGTA GAAGAAGACGGCAGCAGAGGGCGCTTCTTC AAACACCCTGTCCAACTCCTGGCACTGACA 
5' untranslated region 
GTAACAGAAGTTAGAAGGGGAAATGT~C  TCTCTGAAGATTACCCAAAGAAAA GTGAT TTGTCATTGC~PTATAGACTGTAAGAAGAG AACATCTCAGAAGTGGAGTCTTACCCTGAA 
BamHI 
TTCTTCAC-CAAGTAAGTACATTTACTATTA TCTTACTATGGGATAGCTTGGTAGAACTAG TTACCAGCAACCTCACTGCTTTTTAAACAA ACAATACCTCTGCTACCACCTCCTGGATCC 
TCATTCCCACAGGAGGCTGTGGCTTCCCGA CATATTTGGAC-CATCATAGTGAGAATTGTG GCCCATTATTTTAAAATATCCTAGATCCTA C-CAAATATTGTTTTTGTGGCq2CGTATTTGA 
Sacl 
GTGGGAAAATCGCTTGAGCTC 
CGTGGTGTTTCATGTTTGTTAGTCCATGCA 
+i 
AGTACTGAGTGAACT_CAAACCCTCTGTAAA 
ATCAAAGGATTTAAAAAAGTC-GAATTT 
AGGCTTGCCCTCAAAC-GAACCCTTAGGGTC 
ATTTCTCAAGCCAGTAAAATTCTAGTGAAA 
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-1187 
-1037 
-887 
-737 
-587 
-437 
-287 
-137 
14 
164 
314 
464 
485 
Figure 2.  Nucleotide  sequence of the hB7.1 5' flanking region. Complete nucleotide sequence of the 3.9-kb PacI-SacI region is hsted. The positions 
of the 5' untranslated  region ofhB7.1 cDNA, alu repeat I, alu repeat II, and the 183-bp hB7.1 enhancer are underlined. Representative restriction endo- 
nuclease sites are shown and the putative transcription start site is underlined and marked as + 1. These sequence data are available from EMBL/Gen- 
Bank/DDBJ under accession number U33208. 
flanking region  and sequences  in the database were found, 
nor was there any significant similarity to the recently pub- 
lished mB7.1  5'  UT  region.  Further sequencing  ofa 1.3-kb 
BamHI-PacI  upstream fragment  (Fig.  1, II1) on one strand 
revealed a region highly similar to the 3'  end of a transpo- 
son element, hne  1, commonly found in intergenic  regions 
of chromosomes (data not shown)  (50,  51).  The full length 
of this transposon is '~6 kb, which could specify two tran- 
scripts in the same transcriptional orientation as hB7.1  (52). 
Two consensus TATAA  elements were present at positions 
-2608  and  -2501  relative  to  the  putative  transcription 
start site without  neighboring  5'  consensus  CCAAT  mo- 
tifs. No TATAA  or initiator sequences were present down- 
stream. 
B7.1  Expression  Correlates with  the Presence of a DNase  I 
Hypersensitive Site in Cultured Cell Lines.  As  an  initial  ap- 
proach to identify tissue-specific  regulatory elements in the 
hB7.1 gene,  the chromatin configuration  of this gene  was 
examined in intact nuclei from various cell types by DNase 
I  hypersensitivity  assays.  Nuclei  from  a  panel  of cultured 
human lines were isolated and digested with various amounts 
of DNase  I. The purified DNA  was then digested with the 
appropriate restriction endonuclease (XhoI, BamHI, or SacI), 
electrophoresed,  blotted,  and hybridized to a 295-bp  ScaI- 
BamHI  probe  spanning  the first exon.  The  cell lines were 
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examined simultaneously by FACS |  analysis for surface B7.1 
expression using the anti-kB7.1  mAb  133  (Table  1). 
As  shown  in  Fig.3  A,  XhoI  digestion  of nuclear  DNA 
gives the expected single 9.5-kb restriction fragment. Treat- 
ment  of nuclear  DNA  from  all  cell  lines  with  increasing 
amounts ofDNase  I results in the progressive disappearance 
of the  full-length  fragment  and  the  appearance  of either 
one or two nuclease-generated  subfragments  of ~1.7  (DH 
site A)  and 4.6  kb  (DH site B.).  Since  the  1.7-kb  subfrag- 
merit was present  in all cell lines  tested,  we  conclude  that 
this new band represents a non-tissue-specific DNase I hyper- 
sensitive site.  However,  the second 4.6-kb  nuclease-gener- 
ated subfragment appeared only in the cell hnes that express 
surface B7.1.  Thus, both fragments are present in the EBV5, 
SKW,  and Raft B7.1-positive  B  cells, whereas the remain- 
ing B7.1-negative  cells  0urkat T  cell,  fibroblast  and carci- 
noma cell hnes,  and pre-B  cell hnes)  have  only the  1.7-kb 
subfragment.  In only a single case, namely the BL30 B  cell, 
did a B7.1-positive  line fail to generate the 4.6-kb  DH  site 
B  subfragment.  It  is  possible  that  unique  factors  interact 
with other elements in this transformed cell line to control 
B7.1  expression.  Indeed,  transfection  of the BL30  cell line 
with  a  construct  containing  the  enhancer  region  repre- 
sented by DH  site B  (described below)  revealed an absence 
of activity  (data not shown).  Aside  from this  one cell line, Table  1.  Summary of the Correlation between Surface B7.1 
Expression and Tissue-specific DNase I Hypersensitive Site B 
Surface 
Cell line  B7.1  DH Site B 
Pre-B  Nalm6  -  - 
R.amos  -  - 
B  BL30  +  - 
EBV5  +  + 
Raft  +  + 
SKW  +  + 
T  Jurkat  -  - 
Fibroblast  GM00637  -  - 
Epitheloid carcinoma  HeLa  -  - 
Hepatocellular carcinoma  HepG2  -  - 
Small cell lung carcinoma  NCI-H146  -  - 
Surface expression of  B7.1 on a panel of  human lymphoid and nonlym- 
phoid cell lines was determined by FACS |  analysis using anti-hB7.1 
mAb 133. Presence or absence ofDNase I hypersensitive site B in the 
hB7.1 5' flanking region of each cell line was determined by Southern 
blot analysis  and listed as +  or -, respectively. 
however, DH  site B  appears to correlate well with the ex- 
pression of the B7.1 gene. 
To map the location of the two DH sites more precisely, 
nuclear  DNA  from  the  P,  aji cell line  was  digested with 
additional restriction endonucleases and hybridized to  the 
same probe used in the DNase I hypersensitivity assays. Di- 
gestion with BamHI  revealed that sites A  and B  are ~0.3 
and  3.2  kb,  respectively, upstream  of the  BamHI  site lo- 
cated 3'  to exon  1  (Fig. 3  B). DH  site A, therefore, is lo- 
cated very near the putative transcription start site mapped 
previously by primer extension. Digestion of  DNase I--treated 
Raji nuclear DNA with SacI revealed a  single 0.6-kb frag- 
ment representing site A. Since site B  is not included in the 
SacI  fragment,  it  can  be  mapped  between  the  upstream 
BamHI and SacI sites to a location ,'-,100 bp 5' to the SacI 
rite, N3 kb upstream of the putative start site. The location 
of the two DH sites is shown schematically in Fig. 3  C. 
Localization of  a Transcriptional  Enhancer at DH Site B.  The 
3.3-kb  SacI  fragment  which  includes  DH  site  A  did not 
have transcriptional activity in Raji cells (Fig. 4  B).  It was 
possible that negative regulatory elements within this region 
were responsible for the  absence of promoter activity. To 
test whether DH  sites A  and B  represented B7.1  enhancer 
elements,  we  therefore  subcloned  a  variety  of fragments 
encompassing one or both of these sites into pSyncatII, an 
expression vector containing a minimal herpes virus tk pro- 
moter fused to the CAT reporter gene. Fragments tested in 
preliminary  experiments  included  a  large  5-kb  BamHI 
fragment containing both sites A and B  and a smaller 2.8-kb 
EcoR.I  fragment  containing  only site B.  The  former  had 
minimal activity whereas the latter gave a threefold increase 
in CAT activity over the vector alone (not shown). A  3.7- 
kb  PacI-BamHI  fragment  which  included  both  DH  sites 
was also inactive (Fig. 4 A, lane  12). 
Figure 3.  DNase I hypersensitive analysis  of 
the  hB7.1 5'  flanking region.  (A) Nondssue- 
specific DH site A and tissue-specific  site B are 
shown in Southern blot analysis  with Xhol-di- 
gested DNAs from both B7.1  + and B7. I- cell 
lines and  (B)  with  BamHI-  or  Sacl-digested 
Kaji DNA. (C) The schematic presentation of 
DH site A and B locations in the 5' flanking re- 
gion, derived from three different restriction di- 
gestions. A  series  of restriction  endonuclease--generated 5'  and 3' 
deletion  fragments  were  therefore  constructed  and  tested 
for transcriptional  activity (Fig. 4  A).  The  1.9-kb BamHI- 
SacI fragment displayed fivefold activity above background 
(Fig.  4  A,  lane  2)  and  further  deletions  of this  fragment 
from  the  5'  end  resulted  in  increasing  levels  of reporter 
gene activity (lanes 3-5). A further deletion to the ApaI site 
deleted DH site B  and abolished activity (Fig. 4 A, lane  6), 
thus  establishing  the  5'  border  of the  enhancer.  Similarly, 
deletions  from the  3'  end of the  active 486-bp  PacI-ApaI 
fragment (Fig. 4 A, lane  7) to the StuI site  183 bp upstream 
abolished  activity  (lane  8).  These  experiments  locahze the 
enhancer  to  a  183-bp  StuI-ApaI fragment  (Fig.  4  A,  lane 
9), which is active in both forward and reverse orientations 
(lanes 5,  11 and 4,  10).  Multiple constructs which included 
the  region  surrounding  DH  site  A  failed  to  provide  evi- 
dence for enhancer function in this location (data not shown). 
Because the transcription start site of the hB7.1 gene had 
been mapped by primer extension to a site  58 nucleotides 
upstream  of the  5'  end  of the  cDNA  sequence  (31),  se- 
quences  upstream  of the  first  exon  were  tested  for  pro- 
moter activity. A  5-kb BamHI fragment and a 3.3-kb  SacI 
fragment  containing  the  first  exon  were  cloned  into  the 
promoterless  pSyncatl  expression vector. Deletion variants 
of the latter  construct generated by restriction  enzyme di- 
gestion,  ranging from N0.5  to  2  kb  of upstream  sequence 
were also produced. This series of constructs was tested for 
promoter  activity  by  transfection  into  the  B7.1-positive 
R.aji  B  lymphoma  cell line.  However,  in  preliminary  ex- 
periments,  no  reporter  gene  activity  was  detected.  Since 
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Figure 4.  hB7.1 enhancer activity in transfected 
Raft cells. (Solid  lines) The 5' flanking region clone 
and its deletion variants used for transfection. Each 
clone is indicated by the size of  restriction fragment 
listed and  only  part of the  length between the 
EcoRI site and exon 1 (black  box) is shown. The ab- 
breviation of  restriction enzymes  used are ApaI (14), 
BamHI (B), EcoP,.I (E), EcoNI (EN), PacI (P), SacI 
(S), Spel (Sp), and Stul (St). Enhancer activity is 
shown either with a heterologous tk promoter (A) 
or with the homologous promoter (B). Cells were 
transfected with 20 ~g of each plasmid DNA. One 
representative CAT assay experiment is shown in 
A. The relative CAT activity of lanes 10 and 11 in 
A and lanes 1-5 in B are calculated based on two 
separate experiments. 
the  failure  to  detect  promoter  activity  might  reflect  the 
presence of dominant negative regulatory elements,  a con- 
struct containing the 486-bp enhancer upstream of a 468-bp 
EcoNI-BamHI fragment including DH site A in place of the 
heterologous  tk promoter was  made,  This  construct  con- 
ferred  transcription  activity,  thus  demonstrating  that  se- 
quences surrounding DH site A  can act as a minimal pro- 
moter.  Neither  the  468-bp  promoter  fragment  nor  the 
486-bp enhancer alone were active (Fig. 4 B). The absence 
of transcriptional  activity  observed  with  the  longer  pro- 
moter fragments  may be  due  to  the  presence  of negative 
regulatory elements  downstream  of the  enhancer,  possibly 
including the alu repeat sequences.  Indeed, removal of the 
alu  sequences  increases  promoter  activity  (Fig.  4  B,  com- 
pare lanes  5  and 2).  The B7.1  promoter has recently been 
shown to be transcriptionally active and to contain six ele- 
ments  within  the  first  150  bp  of the  promoter  that  are 
bound by nuclear proteins; one of them is NF-KB (53). 
The  B7.1  Enhancer  is  Cell  Type  Specific and  Inducible  by 
cAMP and LPS.  B7.1  expression  is  strictly  cell  type  spe- 
cific.  To  test  the  tissue  specificity  of the  enhancer  region 
defined  above,  transient  transfections  of several  constructs 
which include  this region were performed  (Fig. 5 A). Cell 
lines tested included the B7.1-negative Jurkat T  lymphoma 
and  HeLa  epithelial  carcinoma and  the  B7.1-positive  hu- 
man B  Lymphoma BA  (54).  The  585-,  282-,  and  183-bp 
constructs  shown  to be  active  in  the  B7.1-positve  kaji  B 
cell line  (Fig.  4 A)  are  also active in the BA cells.  No en- 
hancer activity from any of the constructs was observed in 
the Jurkat or HeLa cell lines,  demonstrating that,  in non-B .> 
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cells,  this  183-bp  region  is  cell  type  specific.  Additional 
B7.1-negative  cell  lines  (Hut78  T  cell  and  G82  glioblas- 
toma)  also  showed  no  activity  (data  not  shown).  Some 
modest (about twofold) enhancer activity was observed in a 
B7.1-negative pre-B cell line Nalm 6 with these constructs, 
but no activity was present when the longer 1.3-, 1.9-, and 
3.7-kb  constructs  were  used  (data  not shown).  This  sug- 
gests that in B7.1-negative B  cells,  there may also be a role 
for negative  elements,  outside  of the  183-bp enhancer,  in 
mediating tissue specificity. We conclude that the enhancer 
located at DH site B within the 183-bp StuI-ApaI fragment 
is cell type specific. 
Multiple  stimuli  increase B7.1  expression in B  cells  and 
macrophages. We have previously shown that the M12 cell 
line  expresses  low levels  of cell  surface  B7.1  that  can  be 
markedly  increased  by  treatment  with  db-cAMP  (27). 
Treatment  of M12 with 30 ~g/ml db-cAMP after transfec- 
tion of the  585-,  282-,  and  183-bp  constructs results  in  a 
modest but reproducible increase in CAT activity (Fig. 5 B). 
We were also able to test the induction of transcription ac- 
tivity  of the  enhancer  by  LPS  in  both  M12  and  in  the 
mouse  B7.1-positive  myeloblast/monocyte-like  cell  line 
M1. Treatment of these cell lines with LPS for 48 h  results 
in a modest but reproducible increase in both surface B7.1 
expression for M1  (not tested for M12)  (Fig. 5  C,  left) and 
CAT activity in both cell lines (Fig 5 C, right and Fig.5 D). 
We also tested the native B7.1 promoter fused to the 486- 
bp enhancer in the  M12  cell line.  Induction of transcrip- 
tion by LPS was also observed in this instance  (Fig.  5 D). 
We conclude that elements within the 183-bp region con- 
fer responsiveness  to  stimuli  known  to  increase  B7.1  ex- 
pression. Further, enhancer activity is not limited to cells of 
the B lineage, but can be observed in B7.1-positive, non-B 
cells,  including the  HTLV-l-transformed B7.1-positive T 
cell MT2  (data not shown).  We could not examine  other 
stimuli  such  as  IL-4 or  Abs  to  CD40,  known  to  induce 
B7.1 expression in B cells,  because of the absence of appro- 
priately  inducible,  transfectable  cell  lines.  To  establish 
whether  this  enhancer  region  also  controls  responsiveness 
to other stimuli  such as  IL-4 and  anti-CD40  may require 
the production of mice transgenic  for the  enhancer to al- 
low the examination of B7.1 regulation in normal cells. 
Deletional and Mutational  Analysis  of the  183-bp Enhancer 
Reveals Several Functional cis Elements.  Initial  experiments  (Fig. 
6 A) employing a series of enhancer deletion constructs with 
subsequent transfection into Raji cells  revealed that nucle- 
Figure  5.  Tissue-specific  hB7.1 enhancer activity in transfected B and 
non-B cells and induction by db-cAMP and LPS. (.4) Selected clones of 
the hB7.1 5' flanking  region and its deletion variants were transfected into 
B7.1-positive or -negative cell lines. (B) Transfected M12 cells were ei- 
ther induced or uninduced with 30 p~g/ml db-cAMP. (C) Enhancer ac- 
tivity in routine myeloid M1 cells and inducibility by LPS. FACS  |  analy- 
sis orB7.1 surface expression on M1 cells either stimulated or unstimulated 
by 10 ng/m] LPS for 48 h and stained with Ab to roB7.1 ( 1G 10) or control 
Ab are shown at left. (D) Comparison of  LPS induction of  the native B7.1 
promoter and the heterologous tk promoter fused to the enhancer in 
M12 cells. The activity is expressed as fold increase over that of the re- 
spective cloning vectors. 
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Mut  12 
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Mut  18 
-3128  -3108  -3088  -3068  -3048  -3028  -3009 
I  I  I  I  I  I  I 
~CTTATAGACATGC~CAGATGAAGTCATATCTAAAAATGAACTTCTAAAC~TCACGGGAC~TCATCTTAGAACATGAAAAACTCCCCTGAAAATTTTTGTCAGTGCAACAGGTTTTGTT 
.TA.GACC.G, 
..........  C.ATGACACG  .................................................................................................... 
....................  T.CTGACC.G  .......................................................................................... 
.................................  TG.CCAG  ................................................................................ 
........................................  TAC.GACC.G  ...................................................................... 
....................................................  ATGACC  .............................................................. 
............................................................  CTATGA.CAG  .................................................. 
......................................................................  CT.TGACC.G  ........................................ 
................................................................................  CTA.GA..A  ............................... 
..........................................................................................  CT.TGACA  ...................... 
....................................................................................................  CT.TGA.C.G  .......... 
..............................................................................................................  CTA,GACCAG 
.......................................................  O  ................................................................ 
B7.1 
Mut  1 
Mut  2 
Mut  3 
Mut  4 
Mut  5 
Mut  6 
Mut  7 
Mut  8 
Mut  9 
Mut  i0 
Mut  II 
Mut  12 
Mat  13 
-3008  -2988  -2968  -2946 
I  I  i  I 
TACTTGGC~&.CAGTGAGCCCAC'I~T~~CAGCAGTCAGGCTAGCACCGTG 
....  C~C..G  ..................................................... 
Mut  14  ...........  TA...C.AG  ........................................... 
Mut  15  ....................  CTATGACC.G  ................................. 
Mut  16  ..............................  CTAT.ACCAG  ....................... 
Mut  17  ........................................  TACTG.CCAG  ............. 
Mut  18  ..................................................  CTA.GA.CAGTG. 
otides at both the 5'  (lanes  5 and 7) and 3'  (lanes 3 and 7) 
ends of  the enhancer were impo~nt. Furthermore, sequences 
internal to  these were  also  involved in  enhancer activity 
(compare lanes 5 with 6 and lanes 3 with 4). Thus, multi- 
ple cis  elements appeared to be present within the  183-bp 
fragment. To precisely delineate the sequences within the 
183-bp  region responsible for enhancer function,  linker- 
scanning mutagenesis was performed. Each linker-scanning 
mutation was 10 bp in length with the exception ofmut 18 
which  was  13  bp  in  length.  Several bases  in  the  10-bp 
stretch were mutated to one of the three remaining nucle- 
otides (see Fig.  6 B) with each resulting sequence checked 
to ascertain that no known promoter motif had been inad- 
vertently created. The wild-type and mutation constructs 
were transfected into the R.aji  cell line and the results  of 
three to five independent experiments are shown in Fig.  6 
C. Two of the 18 mutations (rout 2 and 16) led to particu- 
larly striking decreases in transcriptional activity of the en- 
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Figure 6.  Mutagenic analysis of the 183-bp B7.1 enhancer. (A) 1Kegiom  of the enhancer were analyzed by deletion mutations as shown in one initial 
experiment. The regions corresponding to linker-scanning mutations 2, 4, 9, 12, and 16 are marked by numbers. (B) The sequence of the hB7.1 en- 
hancer and mutations indicated by nucleotide changes. The NF-KB binding site is underlined. (C) The enhancer activities of linker-scanning mutants in 
transfected Raji cells. 15 g~g ofplasmid DNA was used for each transfection. The relative CAT activity of rout 2, 4, 9, 12, and 16 is calculated based on 
five separate experiments. (D) Nucleotide sequences of these regions as well as that of region 3. 
hancer,  whereas three additional  mutations  (mut 4,  9,  and 
12) also reproducibly decreased enhancer activity in five in- 
dependent  experiments.  The  locations  of these  mutations 
(Fig. 6  B) are consistent with the deletion data in Fig. 6 A. 
Several additional mutations also modestly decreased activ- 
ity  (mut 3,  5,  and  17).  Inspection of the  mut 2,  4,  9,  12, 
and 16 sequences  (Fig. 6 D) reveals that site 16 is a consen- 
sus NF-KB element that is identical both in its core nude- 
otides and in the flanking nucleotides  to the NF-KB site in 
the  IgK  enhancer.  Mutation  of this  element  resulted  in 
>70%  abolition  of enhancer  activity.  The remaining  four 
sequences do not bear homology to known promoter mo- 
tifs  as  checked  against  sequences  in  the  database.  A  se- 
quence  with  a  7/8  nucleotide  match to a  cAMP  response 
element  is  also  present  in  the  enhancer,  but  mutation  of 
this element (rout 3) has minimal effect on enhancer activity 
in 1Kaji cells. 
Members  of the  NF-KB  Family  Bind  to  the  B7.1  NF-KB 
Site.  Using an oligonucleotide  corresponding to the con- 
sensus NF-KB element mutated in site 16 as a probe, EMSAs 
were performed with nuclear extracts from the B7.1-posi- 
tive Raji cell hne  (Fig. 7 A, le~). A  DNA-protein  complex 
could be observed with  extracts from 1Kaji (Fig.  7 A),  but 
not with nuclear extracts from Jurkat  (not shown)  that mi- 
grates similarly to a complex observed with the IgK NF-KB 
site (Fig.7, right). That this complex was specific was shown 
by the  ability  of a  10-100-fold  molar  excess  of unlabeled 
wild-type  NF-KB  oligonucleotides,  but  not  an oligonucle- 
otide  from the  unrelated  IL-4 promoter,  to prevent  com- 
plex formation (Fig. 7 A). The multimember NF-KB ram- 
fly  includes  homologous  proteins  termed  p50,  p52,  p65, 
c-lKel, and IKelB. Various combinations of homo- and het- 
erodimers of these family members may activate or repress 
NF-KB-dependent  gene  transcription  (55,  56).  To deter- 
mine which family members present in Raji cells bound to 
this site, supershift EMSA experiments were performed us- 
ing  antisera  to  the  p50,  p52,  p65,  c-IKel,  and  RelB  pro- 
teins. Fig. 7 B demonstrates that two complexes can be ob- 
served (arrows). The faster migrating lower complex (Fig. 7 
B, /)  is supershifted by Abs to p50,  c-Rel,  and 1KelB,  sug- 
gesting  it  is  a  homo-  or  heterodimer  of these  proteins 
whereas the slower migrating upper complex (I/) is super- 
shifted by the  Abs to p50  and p65,  suggesting  it is a  het- 
erodimer composed of p50 and p65 proteins.  Such homo- 
and heterodimers  of various  NF-KB family members have 
been previously observed to bind NF-KB target sequences 
in many promoters (47, 57, 58).  The p52 protein is not in- 
volved in binding to the B7.1  NF-KB site as judged by the 
failure  of the  anti-p52  Ab  to  affect  complex  formation. 
Cotransfection  of M12  B  cells with  the  183-bp  enhancer 
and  NF-KB  subunits  p50  or  p65  expression  constructs 
demonstrated that p65 transactivates the enhancer,  whereas 
p50 does not (Fig. 7  C). Further, p50 decreases transactiva- 
tion  by p65,  consistent  with  the  known  role  of p65  as  a 
transcriptional activator and p50 as a repressor. 
This is the first description  to our knowledge  of regula- 
tory elements that control expression of the gene encoding 
the B7.1  costimulatory molecule. The presence of a tissue- 
specific DNase I hypersensitive site N3 kb upstream of the 
transcription  start site  of the  human  B7.1  gene led  to the 
identification  of a  cell type-specific enhancer  region.  This 
183-bp region was both cell type specific and responsive to 
two distinct stimuli (LPS and db-cAMP) known to regulate 
B7.1  expression.  Site-directed  mutagenesis  revealed  the 
presence of multiple cis elements within this region, one of 
which was a NF-KB consensus sequence. This element binds 
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Figure 7.  EMSA of the NF-mB site  in the hB7.1 enhancer. (A) EMSA 
complexes are shown using Raft nuclear extract and 32p-labeled  probes of 
the hB7.1 and IgK enhancer NF-KB sequences. The complexes are com- 
peted by excess amounts of unlabeled competitors as indicated. (B) Inhi- 
bition of NF-KB protein binding to the hB7.1 enhancer by antisera to 
NF-KB family member p50, p52, p65, c-Rel (Rel), and Rel-B. The fast- 
migrating NF-KB complex I was blocked by mAb to p50,  c-R_el, and 
Rel-B, and the slow-migrating complex II was blocked by mAb to p50 
and p65. (C) Cotransfection of M12 cells with the 183-bp StuI-ApaI en- 
hancer construct (1 ~g) and NF-KB p50 and p65 (5 ~g) constructs dem- 
onstrates transactivation  by p65 and repression by pS0. 
several members of the NF-KB family in B7.1-positive cells 
and can be transactivated by the p65 subunit. 
The NF-rd3 family of transcription factors has been shown 
to be critical for cell development, differentiation, and the 
response to multiple stimuli. The five members of this fam- 
ily-p50,  p52,  p65,  c-Rel,  and RelB--all contain  a  Rel- 
homology domain  required for binding to  DNA.  NF-KB 
members  are  present ubiquitously in  the  cytosol of many 
different cell types where they form a  stable complex with 
the Imt3ot and Ir  inhibitor proteins (59, 60). Activation by 
mitogenic factors leads to phosphorylation and degradation 
of IKB  and  subsequent  translocation  of NF-KB  proteins 
into the nucleus (61-64). Various homo- and heterodimers 
of nuclear  NF-KB  members  are  potent  transactivators  or 
repressors for many developmentally regulated genes. B7.1 
expression is also developmentally regulated and responsive 
to  stimuli  known  to  increase  nuclear  NF-KB  activity. 
These stimuli include LPS  (65),  cross-linking of CD40  on 
B cells by soluble CD40 ligand (66, 67), or ligation of B  cell 
surface Ig (68).  The induction of NF-KB activity in T  cells 
is regulated by HTLV-1  Tax (69).  Mature activated B  cells 
which  contain constitutive nuclear NF-KB activity are the 
major site of expression of B7.1  (56, 70, 71).  Thymic den- 
dritic cells, the other cell type that constitutively expresses 
B7.1,  are  critically dependent  of Rel-B  activity since Rel 
B-deficient mice have recently been shown to lack mature 
dendritic cells (72). Thus, B7.1  expression appears to paral- 
lel NF-KB activity, consistent with a convergence of signal 
transduction  for  BT.l-inducing  stimuli  on  this  family  of 
transcription  factors.  However,  our  data  clearly  indicate 
that other cis elements also control B7.1  expression. Several 
additional  cis  elements  with  no  obvious  homology  to 
known  promoter  motifs  were  critical  for  functional  en- 
hancer  activity.  Now  that  a  BT.l-specific  enhancer  that 
functions  in  concert  with  a  mimimal  promoter  has  been 
delineated,  identification of the  factors  that  bind  to  these 
additional  elements  will  be  key  in  further  understanding 
the regulation of this important costimulatory molecule. 
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